Female infertility, unespecified
Conditions
Interventions
Patients will be randomly divided into two groups
a group that will use oral didrogesterone and another micronized vaginal progesterone. Through the sample calculation, the result was 21 per group, considering a power of 90% and a significance level
Drug
Sponsors
Centro de Referência da Saúde da Mulher
Faculdade de Ciências Médicas da Santa Casa de São Paulo
Eligibility
Sex/Gender
Female
Age
21 Years to 50 Years
Inclusion criteria
Inclusion criteria: Patients undergoing embryo cryopreservation and thawed embryo transfer due to risk of ovarian hyperstimulation syndrome; excess embryos after pregnancy failure in the fresh transfer; loss of transfer by safe endometrium; who underwent preimplantation genetic testing.
Exclusion criteria
Exclusion criteria: Women with an endometrium smaller than 7 mm after endometrial preparation with estrogen. Patients with a history of recurrent miscarriages; severe male factor; uterine diseases; presence of hydrosalpinx. Patients who had a dominant follicle even with estrogen administration.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| It is expected to improve the results of assisted reproduction techniques, with an increase in pregnancy rates and live births. | — |
Secondary
| Measure | Time frame |
|---|---|
| It is expected that the patient will be able to choose the progesterone administration route, without loss of treatment effectiveness, improving her satisfaction. | — |
Countries
Brazil
Contacts
Public ContactLuma Macedo
Faculdade de Ciências Médicas da Santa Casa de São Paulo
Outcome results
None listed